[Code of Federal Regulations]
[Title 40, Volume 14]
[Revised as of July 1, 2003]
From the U.S. Government Printing Office via GPO Access
[CITE: 40CFR79.54]

[Page 503-506]
 
                   TITLE 40--PROTECTION OF ENVIRONMENT
 
         CHAPTER I--ENVIRONMENTAL PROTECTION AGENCY (CONTINUED)
 
PART 79--REGISTRATION OF FUELS AND FUEL ADDITIVES--Table of Contents
 
            Subpart F--Testing Requirements for Registration
 
Sec. 79.54  Tier 3.

    (a) General Criteria for Requiring Tier 3 Testing. (1) Tier 3 
testing shall be required of a manufacturer or group of manufacturers at 
EPA's discretion when remaining uncertainties as to the significance of 
observed health effects, welfare effects, and/or emissions exposures 
from a fuel or fuel/additive mixture interfere with EPA's ability to 
make reasonable estimates of the potential risks posed by emissions from 
the fuel or additive products. Tier 3 testing may be conducted either on 
an individual basis or a group basis. If performed on a group basis, EPA 
may require either the same representative to be used in Tier 3 testing 
as was used in Tier 2 testing or may select a different member or 
members of the group to represent the group in the Tier 3 tests.
    (2) In addition to the criteria specific to particular tests as 
summarized and detailed in the testing guidelines (Secs. 79.62 through 
79.68), EPA may consider a number of factors (including, but not limited 
to):
    (i) The number of positive and negative outcomes related to each 
endpoint;
    (ii) The identification of concentration-effect relationships;
    (iii) The statistical sensitivity and significance of such studies;
    (iv) The severity of the observed effects (e.g., whether the effects 
would be likely to lead to incapacitating or irreversible conditions);
    (v) The type and number of species included in the reported tests;
    (vi) The consistency and clarity of apparent mechanisms, target 
organs, and outcomes;

[[Page 504]]

    (vii) The presence or absence of effective health test control data 
for base-fuel-only versus additive/base fuel mixture comparisons;
    (viii) The nature and amount of known toxic agents in the emissions 
stream; and
    (ix) The observation of lesions which specifically implicate 
inhalation as an important exposure route.
    (3) Consideration of exposure. EPA retains discretion to consider, 
in addition to available toxicity data, any Tier 1 data on potential 
exposures to emissions from a particular fuel or fuel additive (or group 
of fuels and/or fuel additives) in determining whether to require Tier 3 
testing. EPA may consider, but is not limited to, the following factors:
    (i) Types and emission rates of speciated emission components;
    (ii) Types and emission rates of combinations of compounds or 
elements of concern;
    (iii) Historical and/or projected production volumes and market 
distributions; and
    (iv) Estimated population and/or environmental exposures obtained 
through extrapolation, modeling, or literature search findings on 
ambient, occupational, or epidemiological exposures.
    (b) Notice. (1) EPA will determine whether Tier 3 testing is 
necessary upon receipt of a manufacturer's (or group's) submittal as 
prescribed under Sec. 79.51(d). If EPA determines on the basis of the 
Tier 1 and 2 data submission and any other available information that 
further testing is necessary, EPA will require the responsible 
manufacturer(s) to conduct testing as described elsewhere in this 
section. EPA will notify the manufacturer (or group) by certified letter 
of the purpose and nature of any proposed testing and of the proposed 
deadline for completing the testing. A copy of the letter will be placed 
in the public record. EPA will provide the manufacturer a 60-day comment 
period after the manufacturer's receipt of such notice. EPA may extend 
the comment period if it appears from the nature of the issues raised 
that further discussion is warranted. In the event that no comment is 
received by EPA from the manufacturer (or group) within the comment 
period, the manufacturer (or group) shall be deemed to have consented to 
the adoption by EPA of the proposed Tier 3 requirements.
    (2) EPA will issue a notice in the Federal Register of its intent to 
require testing under Tier 3 for a particular fuel or additive 
manufacturer and that a copy of the letter to the manufacturer outlining 
the Tier 3 testing for that manufacturer is available in the public 
record for review and comment. The public shall have a minimum of thirty 
(30) days after the publication of this notice to comment on the 
proposed Tier 3 testing.
    (3) EPA will include in the public record a copy of any timely 
comments concerning the proposed Tier 3 testing requirements received 
from the affected manufacturer or group or from the public, and the 
responses of EPA to such comments. After reviewing all such comments 
received, EPA will adopt final Tier 3 requirements by sending a 
certified letter describing such final requirements to the manufacturer 
or group. EPA will also issue a notice in the Federal Register 
announcing that it has adopted such final Tier 3 requirements and that a 
copy of the letter adopting the requirements has been included in the 
public record.
    (4) Prior to beginning any required Tier 3 testing, the manufacturer 
shall submit detailed test protocols to EPA for approval. Once EPA has 
determined the Tier 3 testing requirements and approves the test 
protocols, any modification to the requirements shall be governed by 
Sec. 79.51(f).
    (c) Carcinogenicity and Mutagenicity Testing. (1) A potential need 
for Tier 3 carcinogenicity and/or mutagenicity testing may be indicated 
if the results of the In vivo Micronucleus Assay, required under 
Sec. 79.64, the In vivo Sister Chromatid Exchange Assay, required under 
Sec. 79.65, the Salmonella mutagenicity assay required under Sec. 79.68, 
or relevant pathologic findings under Sec. 79.62 demonstrate a 
statistically significant dose-related positive response as compared 
with appropriate controls. Alternatively, Tier 3 carcinogenicity testing 
and/or mutagenicity testing may be required if there are positive

[[Page 505]]

outcomes for at least one concentration in two or more of the tests 
required under Secs. 79.64, 79.65, and 79.68.
    (2) The testing for carcinogenicity required under this paragraph 
may, at EPA's discretion, be conducted in accordance with 40 CFR 
798.3300 or 798.3320, or their equivalents (see suggested references 
following each health effects testing guideline). The testing for 
mutagenicity required under this paragraph may likewise be conducted in 
accordance with 40 CFR 798.5195, 798.5500, 798.5955, 798.7100, and/or 
other suitable equivalent testing (see suggested references following 
each health effects testing guideline). EPA may supplement or modify 
guidelines as required to ensure that the prescribed testing addresses 
the identified areas of concern.
    (d) Reproductive and Teratological Effects Testing. (1) A potential 
need for Tier 3 testing may be indicated if the results of the Fertility 
Assessment/Teratology study required under Sec. 79.63 or relevant 
findings under Sec. 79.62 demonstrate, in comparison with appropriate 
controls, a statistically significant dose-related positive response in 
one or more of the possible test outcomes. Similarly, Tier 3 testing may 
be indicated if statistically significant positive results are confined 
to either sex, or to the fetus as opposed to the pregnant adult.
    (2) The testing for reproductive and teratological effects required 
under this paragraph may, at EPA's discretion, be conducted in 
accordance with 40 CFR 798.4700 and/or by performance of a reproductive 
assay by continuous breeding. These guidelines may be modified or 
supplemented by EPA as required to ensure that the prescribed testing 
addresses the identified areas of concern.
    (e) Neurotoxicity Testing. (1) A potential need for Tier 3 
neurotoxicity testing may be indicated if either the results of the 
Neuropathology Assessment required under Sec. 79.67 shows concentration-
related effects in exposed animals or the Glial Fibrillary Acidic 
Protein Assay required under Sec. 79.66 demonstrates a statistically 
significant concentration-related positive response as compared with 
appropriate controls. Similarly, Tier 3 neurotoxicity testing may be 
indicated if relevant results under Sec. 79.62 demonstrate a 
statistically significant positive response in comparison to appropriate 
controls.
    (2) The testing for neurotoxicity required under this paragraph may, 
at EPA's discretion, be conducted in accordance with 40 CFR 798.3260 and 
40 CFR part 798 subpart G. These guidelines may be modified or 
supplemented by EPA as required to ensure that the prescribed testing 
addresses the identified areas of concern.
    (f) General and Pulmonary Toxicity Testing. (1) A potential need for 
Tier 3 general and/or pulmonary toxicity testing may be indicated if, in 
comparison with appropriate controls, the results of the Subchronic 
Toxicity Study, pursuant to Sec. 79.62, demonstrate abnormal gross 
analysis or histopathological findings (especially as relates to lung 
pathology from whole-body preserved test animals) or persistence or 
delayed occurrence of toxic effects beyond the exposure period.
    (2) A potential need for Tier 3 testing with respect to other organ 
systems or endpoints not addressed by specific Tier 2 tests, e.g., 
hepatic, renal, or endocrine toxicity, may be demonstrated by findings 
in the Tier 2 Subchronic Toxicity Study (pursuant to Sec. 79.62) or by 
findings in the Tier 1 literature search of adverse functional, 
physiologic, metabolic, or histopathologic effects of fuel or additive 
emissions to such other organ systems or any other information available 
to EPA. In addition, findings in the Tier 1 emission characterization of 
significant levels of a known toxicant to such other organ systems and 
endpoints may also indicate a need for relevant health effects testing. 
The testing required under this paragraph may include tests conducted in 
accordance with 40 CFR 798.3260 or 798.3320. These guidelines may be 
modified or supplemented by EPA as necessary to ensure that the 
prescribed testing addresses the identified areas of concern.
    (3) The testing for general/pulmonary toxicity required under this 
paragraph may, at EPA's discretion, be conducted in accordance with 40 
CFR 798.2450 or

[[Page 506]]

798.3260. These guidelines may be modified or supplemented by EPA as 
necessary to ensure that the prescribed testing addresses the identified 
areas of concern. Pulmonary function measurements, host defense assays, 
immunotoxicity tests, cell morphology/morphometry, and/or enzyme assays 
of lung lavage cells and fluids may be specifically required.
    (g) Other Tier 3 Testing. (1) A manufacturer or group may be 
required to use up-to-date modeling, sampling, monitoring, and/or 
analytic approaches at the Tier 3 level to provide:
    (i) Estimates of exposures to the emission products of a fuel or 
fuel additive or group of products;
    (ii) The expected atmospheric transformation products of such 
emissions; and
    (iii) The environmental partitioning of such emissions to the air, 
soil, water, and biota.
    (2) Additional emission characterization may be required if 
uncertainty over the identity of chemical species or rate of their 
emission interferes with reasonable judgments as to the presence and/or 
concentration of potentially toxic substances in the emissions of a fuel 
or fuel additive. The required tests may include characterization of 
additional classes of emissions, the characterization of emissions 
generated by additional vehicles/engines of various technology mixes 
(e.g., catalyzed versus non-catalyzed emissions), and/or other more 
precise analytic procedures for identification or quantification of 
emissions compounds. Additional emissions testing may also be required 
to evaluate concerns which may arise regarding the potential effects of 
a fuel or fuel additive on the performance of emission control 
equipment.
    (3) A manufacturer or group may be required to conduct biological 
and/or exposure studies at the Tier 3 level to evaluate directly the 
potential public welfare or environmental effects of the emissions of a 
fuel or additive, if significant concerns about such effects arise as a 
result of EPA's review of the literature search or emission 
characterization findings in Tier 1 or the results of the toxicological 
tests in Tier 2.
    (4) With regard to group submittals, Tier 3 studies on a fuel or 
additive product(s) other than the originally specified group 
representative may be required if specific differences in the product's 
composition indicate that its emissions may have different toxicologic 
properties from those of the original group representative.
    (5) Additional emission characterization and/or toxicologic tests 
may be required to evaluate the impact of different vehicle, engine, or 
emission control technologies on the observed composition or health or 
welfare effects of the emissions of a fuel or additive.
    (6) Toxicological tests on individual emission products may be 
required.
    (7) Upon review of information submitted for an aerosol product 
under Sec. 79.58(e), emissions characterization, exposure, and/or 
toxicologic testing at a Tier 3 level may be required.
    (8) A manufacturer which qualifies for and has elected to use the 
special provisions for the products of small businesses (pursuant to 
Sec. 79.58(d)) may be required to conduct emission characterization, 
exposure, and/or toxicologic studies at the Tier 3 level for such 
products, as specified in Sec. 79.58(d)(4).
    (9) The examples of potential Tier 3 tests described in this section 
do not in any way limit EPA's broad discretion and authority under Tier 
3.